Is PLRX or ELDN more profitable?

Pliant Therapeutics' return on equity of -58.11% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -58.11% -44.37% Eledon Pharmaceuticals N/A -116.97% -41.91%

Does the media prefer PLRX or ELDN?

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.93 beat Eledon Pharmaceuticals' score of 0.84 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eledon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PLRX or HUMA?

In the previous week, Humacyte had 19 more articles in the media than Pliant Therapeutics. MarketBeat recorded 21 mentions for Humacyte and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.93 beat Humacyte's score of 0.80 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZNTL or PLRX more profitable?

Zentalis Pharmaceuticals' return on equity of -53.61% beat Pliant Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -53.61% -40.67% Pliant Therapeutics N/A -58.11% -44.37%

Is PLRX or AVXL more profitable?

Anavex Life Sciences' return on equity of -38.76% beat Pliant Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -58.11% -44.37% Anavex Life Sciences N/A -38.76% -35.01%

Pliant Therapeutics (PLRX) Competitors

$1.14 +0.01 (+0.44%)

As of 10:44 AM Eastern

Compare

PLRX vs. ELDN, TKNO, HUMA, ZNTL, and AVXL

Should you buy Pliant Therapeutics stock or one of its competitors? MarketBeat compares Pliant Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pliant Therapeutics include Eledon Pharmaceuticals (ELDN), Alpha Teknova (TKNO), Humacyte (HUMA), Zentalis Pharmaceuticals (ZNTL), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry.

How does Pliant Therapeutics compare to Eledon Pharmaceuticals?

Pliant Therapeutics (NASDAQ:PLRX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.93 beat Eledon Pharmaceuticals' score of 0.84 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eledon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pliant Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 164.32%. Eledon Pharmaceuticals has a consensus target price of $9.67, suggesting a potential upside of 173.46%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 6.4% of Pliant Therapeutics shares are owned by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals has lower revenue, but higher earnings than Pliant Therapeutics. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	44.48	-$149.34M	-$1.84	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

Pliant Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Pliant Therapeutics' return on equity of -58.11% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

Summary

Eledon Pharmaceuticals beats Pliant Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Pliant Therapeutics compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Alpha Teknova has higher revenue and earnings than Pliant Therapeutics. Alpha Teknova is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	5.44	-$17.26M	-$0.32	N/A
Pliant Therapeutics	$1.58M	44.48	-$149.34M	-$1.84	N/A

Alpha Teknova has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 12.5% of Alpha Teknova shares are held by company insiders. Comparatively, 6.4% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pliant Therapeutics has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-41.07%	-24.32%	-16.34%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Alpha Teknova presently has a consensus price target of $8.00, suggesting a potential upside of 94.65%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 164.32%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Pliant Therapeutics had 1 more articles in the media than Alpha Teknova. MarketBeat recorded 2 mentions for Pliant Therapeutics and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.89 beat Pliant Therapeutics' score of 0.93 indicating that Alpha Teknova is being referred to more favorably in the media.

Company	Overall Sentiment
Alpha Teknova	Very Positive
Pliant Therapeutics	Positive

Summary

Alpha Teknova beats Pliant Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Pliant Therapeutics compare to Humacyte?

Pliant Therapeutics (NASDAQ:PLRX) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Humacyte has higher revenue and earnings than Pliant Therapeutics. Humacyte is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	44.48	-$149.34M	-$1.84	N/A
Humacyte	$2.02M	120.59	-$40.83M	-$0.57	N/A

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 6.4% of Pliant Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pliant Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market.

Pliant Therapeutics has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Pliant Therapeutics' return on equity of -58.11% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

Pliant Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 164.32%. Humacyte has a consensus price target of $6.57, suggesting a potential upside of 500.13%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Humacyte had 19 more articles in the media than Pliant Therapeutics. MarketBeat recorded 21 mentions for Humacyte and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.93 beat Humacyte's score of 0.80 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Humacyte beats Pliant Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Pliant Therapeutics compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Zentalis Pharmaceuticals has a beta of 1.97, suggesting that its share price is 97% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Zentalis Pharmaceuticals presently has a consensus price target of $5.83, suggesting a potential upside of 45.65%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 164.32%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Zentalis Pharmaceuticals' return on equity of -53.61% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
Pliant Therapeutics	N/A	-58.11%	-44.37%

97.3% of Pliant Therapeutics shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Pliant Therapeutics had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 2 mentions for Pliant Therapeutics and 1 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.89 beat Pliant Therapeutics' score of 0.93 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Zentalis Pharmaceuticals	Very Positive
Pliant Therapeutics	Positive

Zentalis Pharmaceuticals has higher revenue and earnings than Pliant Therapeutics. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.23	-$137.06M	-$1.73	N/A
Pliant Therapeutics	$1.58M	44.48	-$149.34M	-$1.84	N/A

Summary

Zentalis Pharmaceuticals beats Pliant Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Pliant Therapeutics compare to Anavex Life Sciences?

Pliant Therapeutics (NASDAQ:PLRX) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Pliant Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 164.32%. Anavex Life Sciences has a consensus price target of $21.33, suggesting a potential upside of 758.48%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 6.4% of Pliant Therapeutics shares are held by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pliant Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Anavex Life Sciences has lower revenue, but higher earnings than Pliant Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	44.48	-$149.34M	-$1.84	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

Anavex Life Sciences' return on equity of -38.76% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Anavex Life Sciences	N/A	-38.76%	-35.01%

In the previous week, Pliant Therapeutics had 1 more articles in the media than Anavex Life Sciences. MarketBeat recorded 2 mentions for Pliant Therapeutics and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.87 beat Pliant Therapeutics' score of 0.93 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Pliant Therapeutics	Positive
Anavex Life Sciences	Very Positive

Summary

Anavex Life Sciences beats Pliant Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Pliant Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRX vs. The Competition

Export

Metric	Pliant Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$70.28M	$3.39B	$6.49B	$12.31B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.62	20.05	24.05	24.76
Price / Sales	44.48	325.48	542.61	168.32
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.38	8.16	10.69	6.90
Net Income	-$149.34M	$23.89M	$3.57B	$337.45M
7 Day Performance	-1.30%	3.66%	1.56%	2.84%
1 Month Performance	-1.30%	1.69%	2.49%	4.78%
1 Year Performance	-17.75%	46.95%	26.51%	33.08%

Pliant Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRX Pliant Therapeutics	2.2253 of 5 stars	$1.14 +0.4%	$3.00 +164.3%	-18.1%	$70.28M	$1.58M	N/A	90
ELDN Eledon Pharmaceuticals	1.7558 of 5 stars	$3.71 -2.6%	$9.67 +160.5%	+24.4%	$294.09M	N/A	N/A	10
TKNO Alpha Teknova	2.5809 of 5 stars	$5.11 -5.4%	$8.00 +56.6%	-23.4%	$289.52M	$40.52M	N/A	240	Positive News High Trading Volume
HUMA Humacyte	3.749 of 5 stars	$1.39 +6.5%	$6.43 +364.2%	-55.5%	$288.62M	$2.04M	N/A	150	News Coverage Analyst Revision Gap Up
ZNTL Zentalis Pharmaceuticals	2.5455 of 5 stars	$3.87 -3.3%	$5.83 +50.8%	+179.9%	$283.32M	N/A	N/A	160	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pliant Therapeutics (PLRX) Competitors

PLRX vs. ELDN, TKNO, HUMA, ZNTL, and AVXL

How does Pliant Therapeutics compare to Eledon Pharmaceuticals?

Summary

How does Pliant Therapeutics compare to Alpha Teknova?

Summary

How does Pliant Therapeutics compare to Humacyte?

Summary

How does Pliant Therapeutics compare to Zentalis Pharmaceuticals?

Summary

How does Pliant Therapeutics compare to Anavex Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pliant Therapeutics (PLRX) Competitors

PLRX vs. ELDN, TKNO, HUMA, ZNTL, and AVXL

How does Pliant Therapeutics compare to Eledon Pharmaceuticals?

Does the media prefer PLRX or ELDN?

Do analysts prefer PLRX or ELDN?

Do institutionals and insiders hold more shares of PLRX or ELDN?

Which has higher valuation and earnings, PLRX or ELDN?

Which has more volatility & risk, PLRX or ELDN?

Is PLRX or ELDN more profitable?

Summary

How does Pliant Therapeutics compare to Alpha Teknova?

Which has higher valuation and earnings, TKNO or PLRX?

Which has more volatility and risk, TKNO or PLRX?

Do institutionals & insiders have more ownership in TKNO or PLRX?

Is TKNO or PLRX more profitable?

Do analysts rate TKNO or PLRX?

Does the media refer more to TKNO or PLRX?

Summary

How does Pliant Therapeutics compare to Humacyte?

Which has higher earnings and valuation, PLRX or HUMA?

Do institutionals and insiders hold more shares of PLRX or HUMA?

Which has more risk and volatility, PLRX or HUMA?

Is PLRX or HUMA more profitable?

Do analysts rate PLRX or HUMA?

Does the media favor PLRX or HUMA?

Summary

How does Pliant Therapeutics compare to Zentalis Pharmaceuticals?

Which has more volatility & risk, ZNTL or PLRX?

Do analysts prefer ZNTL or PLRX?

Is ZNTL or PLRX more profitable?

Do insiders & institutionals have more ownership in ZNTL or PLRX?

Does the media refer more to ZNTL or PLRX?

Which has stronger earnings & valuation, ZNTL or PLRX?

Summary

How does Pliant Therapeutics compare to Anavex Life Sciences?

Do analysts rate PLRX or AVXL?

Do institutionals and insiders hold more shares of PLRX or AVXL?

Which has more risk & volatility, PLRX or AVXL?

Which has stronger valuation & earnings, PLRX or AVXL?

Is PLRX or AVXL more profitable?

Does the media favor PLRX or AVXL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools